Literature DB >> 22951588

Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma.

Roxanne E Jensen1, Neeraj K Arora, Keith M Bellizzi, Julia H Rowland, Ann S Hamilton, Noreen M Aziz, Arnold L Potosky.   

Abstract

BACKGROUND: Non-Hodgkin lymphoma (NHL) is the fifth most common cancer among men and women. Patients with aggressive NHL receive intense medical treatments that can significantly compromise health-related quality of life (HRQOL). However, knowledge of HRQOL and its correlates among survivors of aggressive NHL is limited.
METHODS: Self-reported data on HRQOL (physical and mental function, anxiety, depression, and fatigue) were analyzed for 319 survivors of aggressive NHL. Survivors 2 to 5 years postdiagnosis were selected from the Los Angeles County Cancer Registry. Bivariate and multivariable methods were used to assess the influence of sociodemographic, clinical, and cognitive health-appraisal factors on survivors' HRQOL.
RESULTS: After accounting for other covariates, marital status was associated with all HRQOL outcomes (P < .05). Younger survivors reported worse mental function and higher levels of depression, anxiety, and fatigue (P < .01). Survivors who had more comorbid conditions or lacked private health insurance reported worse physical and mental function and higher levels of depression and fatigue (P < .05). Survivors who experienced a recurrence reported worse physical function and higher levels of depression and fatigue (P < .05). With the exception of a nonsignificant association between perceived control and physical function, greater perceptions of personal control and health competence were associated significantly with more positive HRQOL outcomes (P < .01).
CONCLUSIONS: The current results indicated that survivors of aggressive NHL who are younger, are unmarried, lack private insurance, or experience greater illness burden may be at risk for poorer HRQOL. Cognitive health-appraisal factors were strongly related to HRQOL, suggesting potential benefits of interventions focused on these mutable factors for this population.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22951588      PMCID: PMC3552112          DOI: 10.1002/cncr.27781

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

Authors:  A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

2.  Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.

Authors:  M Jerkeman; S Kaasa; M Hjermstad; S Kvaløy; E Cavallin-Stahl
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

3.  Barriers to information access, perceived health competence, and psychosocial health outcomes: test of a mediation model in a breast cancer sample.

Authors:  Neeraj K Arora; Pauley Johnson; David H Gustafson; Fiona McTavish; Robert P Hawkins; Suzanne Pingree
Journal:  Patient Educ Couns       Date:  2002-05

Review 4.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

Authors:  Ingvar Bjelland; Alv A Dahl; Tone Tangen Haug; Dag Neckelmann
Journal:  J Psychosom Res       Date:  2002-02       Impact factor: 3.006

Review 5.  Prevalence of depression in patients with cancer.

Authors:  Mary Jane Massie
Journal:  J Natl Cancer Inst Monogr       Date:  2004

6.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

7.  Quality of life in adult survivors of lung, colon and prostate cancer.

Authors:  C A Schag; P A Ganz; D S Wing; M S Sim; J J Lee
Journal:  Qual Life Res       Date:  1994-04       Impact factor: 4.147

8.  General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.

Authors:  David F Penson; Ziding Feng; Alan Kuniyuki; Dale McClerran; Peter C Albertsen; Dennis Deapen; Frank Gilliland; Richard Hoffman; Robert A Stephenson; Arnold L Potosky; Janet L Stanford
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  A relationship between perceived self-efficacy and quality of life in cancer patients.

Authors:  A J Cunningham; G A Lockwood; J A Cunningham
Journal:  Patient Educ Couns       Date:  1991-02

10.  Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory.

Authors:  D M Hann; M M Denniston; F Baker
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

View more
  27 in total

1.  Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database.

Authors:  Cécile Conte; Manuela Rueter; Guy Laurent; Robert Bourrel; Maryse Lapeyre-Mestre; Fabien Despas
Journal:  Support Care Cancer       Date:  2016-07-19       Impact factor: 3.603

2.  Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey.

Authors:  Donna M Posluszny; Mary Amanda Dew; Ellen Beckjord; Dana H Bovbjerg; John E Schmidt; Carissa A Low; Amy Lowery; Stephanie A Nutt; Sarah R Arvey; Ruth Rechis
Journal:  J Health Psychol       Date:  2015-04-06

3.  Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand.

Authors:  Pichitra Lekdamrongkul; Kanaungnit Pongthavornkamol; Alex Molassiotis; Aurawamon Sriyuktasuth; Noppadol Siritanaratkul; Natkamol Chansatitporn
Journal:  Support Care Cancer       Date:  2021-04-28       Impact factor: 3.603

4.  An exploratory path model of the relationships between positive and negative adaptation to cancer on quality of life among non-Hodgkin lymphoma survivors.

Authors:  Ashley Leak Bryant; Sophia K Smith; Catherine Zimmer; Jamie Crandell; Coretta M Jenerette; Donald E Bailey; Sheryl Zimmerman; Deborah K Mayer
Journal:  J Psychosoc Oncol       Date:  2015

5.  Cognitive function and its relationship to other psychosocial factors in lymphoma survivors.

Authors:  Dorothy Krolak; Barbara Collins; Lorelle Weiss; Cheryl Harris; Richard Van der Jagt
Journal:  Support Care Cancer       Date:  2016-11-11       Impact factor: 3.603

6.  Gender, race, BMI, and social support in relation to the health-related quality of life of cancer survivors: a report from the American Cancer Society's Study of Cancer Survivors II (SCS-II).

Authors:  Ruth P Westby; Carla J Berg; Corinne Leach
Journal:  Qual Life Res       Date:  2015-08-20       Impact factor: 4.147

7.  Quality of life amongst lymphoma survivors in a developing country.

Authors:  Diana L C Ng; Y C Leong; Gin Gin Gan
Journal:  Support Care Cancer       Date:  2016-07-26       Impact factor: 3.603

8.  Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong.

Authors:  Shing Fung Lee; Miguel Angel Luque-Fernandez; Yu Hui Chen; Paul J Catalano; Chi Leung Chiang; Eric Yuk-Fai Wan; Ian Chi-Kei Wong; Ming Hui Chen; Andrea K Ng
Journal:  Blood Adv       Date:  2020-10-27

9.  Gender-specific quality of life after cancer in young adulthood: a comparison with the general population.

Authors:  Kristina Geue; Annekathrin Sender; Ricarda Schmidt; Diana Richter; Andreas Hinz; Thomas Schulte; Elmar Brähler; Yve Stöbel-Richter
Journal:  Qual Life Res       Date:  2013-11-07       Impact factor: 4.147

10.  The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry.

Authors:  P A J Vissers; M S Y Thong; F Pouwer; M M J Zanders; J W W Coebergh; L V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2013-08-06       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.